Effects and safety of pueraria mirifica gel on vaginal health and lower urinary tract in postmenopausal women

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20141013003

Enrollment

Unknown

Registered

2014-10-13

Start date

2014-10-20

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urogenital atrophy vaginal atrophy urethral atrophy urinary incontinence pueraria mirifica

Interventions

Pueraria mirifica,lubricant vaginal application

Experimental Biological/Vaccine,Placebo Comparator Biological/Vaccine

Study Group,Control

Eligibility

Sex/Gender

Female

Age

50 Years to 80 Years

Inclusion criteria

Inclusion criteria: postmenopausal women urogenital atrophy

Exclusion criteria

Exclusion criteria: not willing to participate

Design outcomes

Primary

Measure	Time frame
Urethral cytology 4 weeks Maturation Index,Urethral blood flow 4 weeks Pulsatility index	—

Secondary

Measure	Time frame
Vaginal cytology 4 weeks Maturation index	—

Countries

Thailand

Contacts

Public ContactJittima Manonai

Faculty of Medicine Ramathibodi Hospital

jittima_pom@yahoo.com02-2012167

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026